CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.

Trial Details

NCT ID

NCT05648019

Phase

PHASE2

Sponsor

KK Women's and Children's Hospital

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Anti-CD19 CAR T-cells

Locations (sample)

Singapore, Singapore|1.28967,103.85007
Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

Eligible disease conditions:
Relapsed or refractory B-cell ALL (all must be satisfied)
Presence of lymphoblasts in bone marrow aspirate by morphologic assessment or positive minimal residual disease at screening.
Relapsed or refractory or ineligible for HSCT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →